248 related articles for article (PubMed ID: 25597708)
1. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
Yang X; Liu G; Huang Y; Chen S; Du J; Jin H
Cardiol Young; 2015 Aug; 25(6):1182-90. PubMed ID: 25597708
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
Chandelia S
Cardiol Young; 2015 Aug; 25(6):1228. PubMed ID: 25904322
[No Abstract] [Full Text] [Related]
3. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
4. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
6. N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement.
Adjagba PM; Desjardins L; Fournier A; Spigelblatt L; Montigny M; Dahdah N
Cardiol Young; 2015 Oct; 25(7):1311-8. PubMed ID: 25544036
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Kong WX; Ma FY; Fu SL; Wang W; Xie CH; Zhang YY; Gong FQ
World J Pediatr; 2019 Apr; 15(2):168-175. PubMed ID: 30809758
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of red blood cell distribution width for coronary artery lesions in patients with Kawasaki disease.
Xu H; Fu S; Wang W; Zhang Q; Hu J; Gao L; Zhu W; Gong F
Cardiol Young; 2016 Aug; 26(6):1151-7. PubMed ID: 26435202
[TBL] [Abstract][Full Text] [Related]
10. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
[TBL] [Abstract][Full Text] [Related]
11. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
Li X; Chen Y; Tang Y; Ding Y; Xu Q; Sun L; Qian W; Qian G; Qin L; Lv H
Eur J Pediatr; 2018 Aug; 177(8):1279-1292. PubMed ID: 29948255
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome.
Baer AZ; Rubin LG; Shapiro CA; Sood SK; Rajan S; Shapir Y; Romano A; Bierman FZ
Arch Pediatr Adolesc Med; 2006 Jul; 160(7):686-90. PubMed ID: 16818833
[TBL] [Abstract][Full Text] [Related]
13. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
14. Prognosis and Risk Factors of Coronary Artery Lesions before Immunoglobulin Therapy in Children with Kawasaki Disease.
Qiu H; Jia C; Wang Z; He Y; Rong X; Wu R; Chu M; Shi H
Balkan Med J; 2020 Oct; 37(6):324-329. PubMed ID: 32720495
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
Brogan P; Levin M
Evid Based Med; 2013 Dec; 18(6):217-8. PubMed ID: 23564929
[No Abstract] [Full Text] [Related]
16. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
17. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
Kobayashi T; Inoue Y; Morikawa A
Nihon Rinsho; 2008 Feb; 66(2):332-7. PubMed ID: 18260333
[TBL] [Abstract][Full Text] [Related]
18. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
Liu F; Ding Y; Yin W
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec; 15(12):1109-12. PubMed ID: 24342209
[TBL] [Abstract][Full Text] [Related]
19. Kawasaki disease shock syndrome: a severe form of Kawasaki disease.
İşgüder R; Doksöz Ö; Bağ Ö; Ağın H; Meşe T; Karaarslan ÜU; Devrim İ
Turk J Pediatr; 2013; 55(3):319-21. PubMed ID: 24217080
[TBL] [Abstract][Full Text] [Related]
20. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
Athappan G; Gale S; Ponniah T
Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
